Randomized Controlled Trial of Follicle-Stimulating Hormone Versus Human Menopausal Gonadotropin in Controlled Ovarian Hyperstimulation for in Vitro Fertilization and Embryo Transfer.
- Author:
Seok Hyun KIM
;
Byung Chul JEE
;
Jae Sook ROH
;
Jae Hoon LEE
;
Chang Suk SUH
;
Young Min CHOI
;
Chang Jae SHIN
;
Jung Gu KIM
;
Shin Yong MOON
;
Jin Yong LEE
;
Yoon Seok CHANG
- Publication Type:Clinical Trial ; In Vitro ; Randomized Controlled Trial ; Original Article
- Keywords:
In vitro fertilization and embryo transfer(IVF-ET);
Controlled ovarian hyperstimulation(COH);
Gonadotropin-releasing hormone(GnRH) agonist;
Human menopausal gonadotropin ( hMG );
Human follicle-stimulating hormone ( hFSH );
Pregnancy rate ( PR )
- MeSH:
Embryo Transfer*;
Embryonic Structures*;
Endometriosis;
Female;
Fertilization;
Fertilization in Vitro*;
Follicle Stimulating Hormone*;
Follicle Stimulating Hormone, Human;
Gonadotropins*;
Humans*;
Infertility;
Oocytes;
Semen Analysis;
Seoul
- From:Korean Journal of Obstetrics and Gynecology
1997;40(1):49-59
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recent evidence suggests that a high level of serum LH during follicular recruitment and development is associated with poor reproductive outcome. Consequently, exogenous LH administration for controlled ovarian hyperstimulation(COH) in in vitro fertilization and embryo transfer(IVF-ET) may be harmful to folliculogenesis. The purpose of this clinical study was to evaluate and compare the efficacy of human menopausal gonadotropin(hMG) and human follicle-stimulating hormone(hFSH) for COH with long protocol of gonadotropin-releasing hormone(GnRH) agonist in IVF-ET program. Randomized clinical trial was performed in 125 patiens undergoing IVF-ET at Seoul National University Hospital from May to Septebmer, 1995. The inclusion criteria of patients included age < 40 years and normal semen analysis, and the study population was also classified into two groups by the etiology of infertility : Group T - 95 patients with only tubal factor and Group O - 30 patients with endometriosis or anovulatory factor. There were no statistically significant differences in dosage(29.0+/-7.9 vs 26.0+/-6.8 ampoules) and duration(12.3+/-1.3 vs 12.2+/-1.5 days) of gonadotropin administration, serum E2 level on hCG day(1,943+/-1,255 vs 1,580+/-1,067 pg/mL), cancellation rate(7.5% vs 6.7%), number of oocytes retrieved(9.9+/-6.0 vs 11.3+/-6.0), fertilization rate(68.4% vs 64.5%), number of embryos transferred(4.7+/-2.0 vs 4.7+/-2.0), and preganancy rate per cycle(26.3% vs 24.4%) and per ET(28.4% vs 26.2%) between hMG(N=80) and hFSH(N=45) Groups. In Group T, no significant differnces in results of IVF-ET were also detected between hMG (N=61) and hFSH(N=34) Groups. In Group O, serum E2 level on hCG day was significantly higher in hMG Group (N=19) compared with hFSH Group(N=11), but other results of IVF-ET were similar in both Groups. As this study could not demonstrate any significant differences in results of IVF-ET between hMG and hFSH when used for COH in IVF-ET program, it could be concluded that hFSH is at least as efficacious as hMG for COH.
